Nothing Special   »   [go: up one dir, main page]

CY2315B1 - New treatments using phenethyl derivatives. - Google Patents

New treatments using phenethyl derivatives.

Info

Publication number
CY2315B1
CY2315B1 CY0300009A CY0300009A CY2315B1 CY 2315 B1 CY2315 B1 CY 2315B1 CY 0300009 A CY0300009 A CY 0300009A CY 0300009 A CY0300009 A CY 0300009A CY 2315 B1 CY2315 B1 CY 2315B1
Authority
CY
Cyprus
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Application number
CY0300009A
Other languages
English (en)
Inventor
Richard Leslie Rudolph
Eric Anthony Muth
Albert Thomas Derivan
Gertrude Virginia Upton
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2315(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CY2315B1 publication Critical patent/CY2315B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CY0300009A 1993-06-28 2003-02-04 New treatments using phenethyl derivatives. CY2315B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
CY2315B1 true CY2315B1 (en) 2003-11-14

Family

ID=22181084

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300009A CY2315B1 (en) 1993-06-28 2003-02-04 New treatments using phenethyl derivatives.

Country Status (15)

Country Link
US (8) US5916923A (de)
EP (3) EP0639374B1 (de)
JP (2) JPH0789851A (de)
KR (1) KR100342762B1 (de)
AT (3) ATE342715T1 (de)
AU (2) AU6592994A (de)
CA (1) CA2126305C (de)
CY (1) CY2315B1 (de)
DE (3) DE69434872T2 (de)
DK (3) DK0639374T3 (de)
ES (3) ES2273764T3 (de)
HK (1) HK1038880B (de)
LV (1) LV12881B (de)
PT (3) PT1738753E (de)
SG (1) SG47711A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DK0667150T3 (da) * 1994-02-14 2003-03-31 Wyeth Corp Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
WO2000003701A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
NZ514612A (en) * 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
PL355502A1 (en) * 1999-12-30 2004-05-04 H.Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101671260A (zh) * 2001-02-12 2010-03-17 惠氏公司 制备o-去甲基-文拉法辛的方法
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
PL370552A1 (en) * 2001-12-05 2005-05-30 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2003278549A1 (en) * 2002-11-28 2004-06-18 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600163A (es) * 2005-04-22 2007-03-14 Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
BRPI0610036A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
US7402687B2 (en) * 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
EP1824815A2 (de) * 2005-10-19 2007-08-29 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von hochreinem 1-[2-dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol-hydrochlorid
ES2549079T3 (es) * 2005-12-01 2015-10-22 Auspex Pharmaceuticals, Inc. Fenetilaminas sustituidas con actividad serotoninérgica y/o norepinefrinérgica
EP1957470A1 (de) 2005-12-05 2008-08-20 Wyeth Verfahren zur selektiven synthese von enantiomeren aus substituierten 1-(2-amino-1-phenyl-ethyl)-cyclohexanolen
BRPI0709159A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento de depressão
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008051558A2 (en) * 2006-10-25 2008-05-02 Wyeth Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment
WO2008140859A1 (en) * 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20110118304A1 (en) * 2007-11-20 2011-05-19 Neurosearch A/S Method for treating over-eating disorders
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140116656A1 (en) * 2012-10-25 2014-05-01 Inhon International Co., Ltd Heat dissipation module and electronic device with the same
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
DE3856295T2 (de) * 1987-10-22 1999-06-17 Massachusetts Institute Of Technology, Cambridge, Mass. Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
CA2039103A1 (en) * 1990-03-29 1991-09-30 David Wayne Robertson Improvements in and relating to the selective occupation of serotonin 1c receptors
JPH07500812A (ja) * 1991-11-15 1995-01-26 セプラコア，インコーポレーテッド 純粋なフルオキセチンのｓ（＋）異性体を用いる方法および組成物
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
US20010053799A1 (en) 2001-12-20
PT1738753E (pt) 2008-06-19
DK0639374T3 (da) 2002-05-06
US6444708B2 (en) 2002-09-03
DE69429895T2 (de) 2002-08-29
EP0639374A3 (de) 1995-08-02
PT1153603E (pt) 2007-01-31
EP0639374A2 (de) 1995-02-22
CA2126305A1 (en) 1994-12-29
DE69434872D1 (de) 2006-11-30
US20020052405A1 (en) 2002-05-02
EP1738753B1 (de) 2008-04-23
SG47711A1 (en) 1998-04-17
PT639374E (pt) 2002-07-31
DE69435095D1 (de) 2008-06-05
US20080176950A1 (en) 2008-07-24
ATE392893T1 (de) 2008-05-15
EP1153603A3 (de) 2003-05-21
EP0639374B1 (de) 2002-02-20
KR950000139A (ko) 1995-01-03
AU5831298A (en) 1998-05-21
ATE213407T1 (de) 2002-03-15
HK1038880A1 (en) 2002-04-04
ES2273764T3 (es) 2007-05-16
US5916923A (en) 1999-06-29
LV12881B (en) 2002-11-20
CA2126305C (en) 2006-10-17
US20010012855A1 (en) 2001-08-09
EP1738753A3 (de) 2007-01-31
US6465524B2 (en) 2002-10-15
US6555586B2 (en) 2003-04-29
AU6592994A (en) 1995-01-05
DE69429895D1 (de) 2002-03-28
HK1038880B (zh) 2006-12-22
US6310101B1 (en) 2001-10-30
US20040110829A1 (en) 2004-06-10
DK1738753T3 (da) 2008-08-11
DE69434872T2 (de) 2007-04-05
ATE342715T1 (de) 2006-11-15
KR100342762B1 (ko) 2002-11-18
EP1153603B1 (de) 2006-10-18
DE69435095T2 (de) 2009-07-02
DK1153603T3 (da) 2006-12-18
JPH0789851A (ja) 1995-04-04
JP2006117689A (ja) 2006-05-11
ES2174864T3 (es) 2002-11-16
EP1153603A2 (de) 2001-11-14
EP1738753A2 (de) 2007-01-03
ES2304041T3 (es) 2008-09-01
US20030181517A1 (en) 2003-09-25
US6730706B2 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
CY2315B1 (en) New treatments using phenethyl derivatives.
IL83691A (en) Acylated quinolinamines, their preparation and pharmaceutical compositions containing them
UA81413C2 (en) Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
ES2037779T3 (es) Procedimiento para preparar nuevos compuestos de amida.
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
GB2174989B (en) Phenoxyethylamine derivatives
ZA87773B (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
MY106786A (en) Novel antiviral tetrahydroimidazo [1,4] benzodiazepin -2- (thi)ones
MX9300782A (es) Proceso para preparar (5-amino-1,2-nihidro metil-3-fenilpirido[3,4-b]pirazin-7-7il) carbamato de etilo quiral